Drugs News and Research

RSS

BioTech Medics begins creating TV and radio commercials for SHBAN Alcohol Free Antiseptic Hand Sanitizer

BioTech Medics, Inc. announced today that they have begun the pre-production stage of creating two minute, sixty second and thirty second direct response TV and radio commercials for nationwide distribution for its proprietary SHBAN™ Alcohol Free Antiseptic Hand Sanitizer.

22 Jan 2010

New study indicates viruses employ a novel mechanism to spread more quickly than thought possible

New video footage of a virus infecting cells is challenging what researchers have long believed about how viruses spread, suggesting that scientists may be able to create new drugs to tackle some viruses.

22 Jan 2010

Physicians take measures to treat ADHD on college campuses across the country

In college, students with attention deficit/hyperactive disorder face an array of challenges—long days and nights of classes, studying and activities, all of which require increasing amounts of concentration.

22 Jan 2010

Controversy around Merck's pricing for its AIDS drug Isentress

The controversy around Merck and Co. Pharmaceuticals’ pricing for its key AIDS drug Isentress — at nearly $13,000 per patient yearly, the most expensive first line AIDS therapy on the US market today — continued this week following Merck’s reaction to recent public criticism of its AIDS drug pricing. Merck ramped up its damage control PR efforts, issuing a press release that sought to rewrite the history of Isentress and deflect attention by claiming AIDS Healthcare Foundation has been unfairly attacking them.

22 Jan 2010

AARP launches Idaho Budget Hotline to oppose budget cuts on healthcare and critical services

Bracing for the impact of more budget cuts from the Governor, the worst may still be ahead for the growing number of Idaho families and the elderly forced to turn to the state for the basics.

22 Jan 2010

Heilongjiang Tianlong Pharmaceutical changes R&D focus to antibiotics and cardiac drugs

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that Heilongjiang Tianlong Pharmaceutical Company ("Tianlong"), the Company's wholly owned subsidiary, will change its R&D focus from external use medicines to antibiotics and cardiac drugs.

22 Jan 2010

Findings may aid in developing therapeutic drugs for stroke and other neurodegenerative diseases

Biomedical scientists from the University of Central Florida and Louisiana State University have identified a way to block a "cell death signal" that they believe triggers brain damage during strokes.

22 Jan 2010

Mice study shows obesity can increase risk of developing liver cancer

Obesity comes with plenty of health risks, but there's one that's perhaps not so well known: an increased risk of developing cancer, and especially certain types of cancer like liver cancer. Now, a group of researchers reporting in the January 22nd issue of the journal Cell, a Cell Press publication, have confirmed in mice that obesity does indeed act as a "bona fide tumor promoter." They also have good evidence to explain how that happens.

22 Jan 2010

FDA accepts ACT Biotech's ACTB1003 IND

ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.

22 Jan 2010

Consistent pattern of cognitive deficits during childhood leads to adult schizophrenia

Years before adults develop schizophrenia, there is a pattern of cognitive difficulties they experience as children, including problems with verbal reasoning, working memory, attention and processing speed.

22 Jan 2010

New study shows VBID program can save money

Value-based insurance design programs — which reduce patient co-payments for highly effective treatments — can break even financially or possibly save money, according to a new study from University of Michigan, Harvard and other researchers.

22 Jan 2010

Reuters examines chronic disease in developing countries, future of drug prices

"Global health projections leave little doubt that chronic diseases are rapidly overtaking infectious diseases, such as malaria, AIDS and tuberculosis (TB), as the world's biggest killers - a shift emphasized by a recent World Health Organization (WHO) report on global health risks," Reuters writes in a story analyzing the future of drug pricing in the developing world. Longer life-spans in developing countries "and changing patterns of food, alcohol and tobacco consumption are creating a 'double burden' for poor nations, piling chronic diseases on top of infectious diseases," the news service writes.

21 Jan 2010

Depomed receives second $500,000 milestone payment from Covidien

Depomed, Inc. announced today that it has received a second $500,000 milestone payment under its worldwide license agreement with Covidien focusing on the exclusive development of four acetaminophen/opioid analgesic combination products utilizing Depomed’s Acuform® gastric retentive drug delivery technology. The most recent payment from Covidien, which was received in December 2009, relates to the development of a formulation for the second product candidate under the collaboration.

21 Jan 2010

Health care companies assess where they stand on health reform after election

The Wall Street Journal reports that several firms reiterated support for a health care reform bill Wednesday, a day after the overhaul's viability was called into question by the victory of Republican Sen.-elect Scott Brown in Massachusetts. "PhRMA, the drug industry association, as well as companies including Pfizer Inc., Johnson & Johnson, WellPoint Inc. and Humana Inc., voiced support for an overhaul of some kind, despite objections among insurers about the efforts to date."

21 Jan 2010

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

BioNumerik Pharmaceuticals, Inc. today announced the treatment of the first patients in a global multi-center Phase III clinical trial of Tavocept (BNP7787) in patients with primary adenocarcinoma of the lung, the most common type of lung cancer. In previous studies, Tavocept demonstrated the potential to substantially increase overall and one year patient survival while concurrently preventing and reducing the incidence and severity of common chemotherapy side-effects as compared to other currently available treatments for advanced lung cancer.

21 Jan 2010

Illicit drug consumption in Europe

Europeans belong to the largest consumers of illicit drugs, absorbing about one fifth of the global heroin, cocaine and cannabis supply, as well as one third of ecstasy production (UNODC World Drug report, 2008). However, the vast majority of Europeans have never tried any illicit substance. In popular perception, illicit drugs still represent alien cultures challenging traditional European patterns, including consumption of our favourite drugs - alcoholic beverages.

21 Jan 2010

Results of two pivotal Phase III clinical trials with oral FTY720 published

Results of the TRANSFORMS and FREEDOMS studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine, providing comprehensive evidence to support the efficacy and safety profile of this first-in-class therapy for multiple sclerosis (MS).

21 Jan 2010

MaMayo Clinic experts available to discuss health issues and concerns related to Olympic Games

Mayo Clinic's medical experts are sources of in-depth expertise and commentary about health issues and background related to the Olympic Games and Olympians. Below is a sampling of Mayo Clinic experts available to discuss numerous topics related to the Olympic Games, including concussions, performance enhancing drugs, sports psychology, joint injuries, etc. Mayo has satellite capability for broadcast requests.

21 Jan 2010

Tufts CSDD: Orphan product designations increased up to 425 in 2006-08

The number of orphan product designations in the U.S. more than doubled during the last decade, reflecting growing interest by pharmaceutical and biotech companies in developing products to treat orphan diseases, according to a study recently completed by the Tufts Center for the Study of Drug Development.

21 Jan 2010

New effort to produce standardized DNA parts for reducing development time of synthetic biology in labs

With seed money from the National Science Foundation (NSF), bioengineers from the University of California, Berkeley, and Stanford University are ramping up efforts to characterize the thousands of control elements critical to the engineering of microbes so that eventually, researchers can mix and match these "DNA parts" in synthetic organisms to produce new drugs, fuels or chemicals.

21 Jan 2010

Drugs News and Research

BioTech Medics begins creating TV and radio commercials for SHBAN Alcohol Free Antiseptic Hand Sanitizer

New study indicates viruses employ a novel mechanism to spread more quickly than thought possible

Physicians take measures to treat ADHD on college campuses across the country

Controversy around Merck's pricing for its AIDS drug Isentress

AARP launches Idaho Budget Hotline to oppose budget cuts on healthcare and critical services

Heilongjiang Tianlong Pharmaceutical changes R&D focus to antibiotics and cardiac drugs

Findings may aid in developing therapeutic drugs for stroke and other neurodegenerative diseases

Mice study shows obesity can increase risk of developing liver cancer

FDA accepts ACT Biotech's ACTB1003 IND

Consistent pattern of cognitive deficits during childhood leads to adult schizophrenia

New study shows VBID program can save money

Reuters examines chronic disease in developing countries, future of drug prices

Depomed receives second $500,000 milestone payment from Covidien

Health care companies assess where they stand on health reform after election

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

Illicit drug consumption in Europe

Results of two pivotal Phase III clinical trials with oral FTY720 published

MaMayo Clinic experts available to discuss health issues and concerns related to Olympic Games

Tufts CSDD: Orphan product designations increased up to 425 in 2006-08

New effort to produce standardized DNA parts for reducing development time of synthetic biology in labs

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News